CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 157 enrolled
Drug / intervention
Alcaftadine 0.25% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01732757
NCT01732757Phase 4Completed
CompareCT.gov

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Allergan·interventional·Posted Nov 26, 2012·Updated Jan 14, 2014

In Brief

A Phase 4 clinical trial evaluating Alcaftadine 0.25%, Olopatadine 0.2%, and 1 other intervention for Conjunctivitis, Allergic. Completed, enrolled 157 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 26, 2012
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.6 years ago

Interventions

Alcaftadine 0.25%drug

One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.

Olopatadine 0.2%drug

One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.

dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%drug

One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.